跳转至内容
Merck
CN

1604803

USP

利托那韦

United States Pharmacopeia (USP) Reference Standard

别名:

1,3-噻唑-5-基甲基 N-[（2S,3S,5S）-3-羟基-5-[[（2S）-3-甲基-2-[[甲基-[（2-丙-2-基-1,3-噻唑-4-基）甲基]氨基甲酰基]氨基]丁酰基]氨基]-1,6-二苯基己基-2-基]氨基甲酸酯

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C37H48N6O5S2
化学文摘社编号:
155213-67-5
分子量:
720.94
MDL number:
MFCD08694944
UNSPSC Code:
41116107
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

利托那韦, United States Pharmacopeia (USP) Reference Standard

SMILES string

[s]1c(nc(c1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@@H](NC(=O)OCc4[s]cnc4)Cc3ccccc3)Cc2ccccc2)C(C)C

InChI

1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

InChI key

NCDNCNXCDXHOMX-XGKFQTDJSA-N

biological source

synthetic

grade

pharmaceutical primary standard

agency

USP

vapor pressure

<0.0000001 kPa ( 25 °C)

API family

ritonavir

form

powder

packaging

pkg of 200 mg

manufacturer/tradename

USP

storage condition

protect from light

color

white to tan

solubility

acetonitrile: slightly soluble
ethanol: freely soluble
methanol: freely soluble
methylene chloride: freely soluble
water: practically insoluble

application(s)

pharmaceutical (small molecule)

format

neat

正在寻找类似产品? 访问 产品对比指南

相关类别

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Ritonavir USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Ritonavir Capsules
  • Ritonavir Tablets
  • Ritonavir Oral Solution
  • Lopinavir and Ritonavir Tablets
  • Lopinavir and Ritonavir Oral Solution

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Ritonavir belongs to the group of protease inhibitors that are widely used in combination with other drugs in the prevention of HIV. Its mode of action involves binding to the active site of the protease enzyme and preventing the further maturation of new viral particles.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lopinavir and Ritonavir Oral Solution
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(4), 2666-2666 (2015)
Ritonavir Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(4), 3920-3920 (2013)
Ritonavir USP Monograph
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 37(4), 3880-3880 (2020)
Lopinavir and Ritonavir Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(4), 2670-2670 (2013)
Ritonavir
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 37(4), 3912-3912 (2020)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持